Ironwood Pharmaceuticals Lowers 2024 Guidance: Now Expects Sales Between $405M-$425M (Prior $435M-$455M) Vs. 447.9M Consensus; Sees Adjusted EBITDA Above $120M

5/9/24 7:31:10 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IRWD alert in real time by email

Ironwood 2024 Financial Guidance. Ironwood has revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate related to the year ended December 31, 2023. Ironwood now expects:

	Prior 2024 Guidance (February 15, 2024)	Revised 2024 Guidance2 (May 9, 2024)
U.S. LINZESS Net Sales3	Low-single digits % growth	Mid-single digits % decline
Total Revenue	$435 to $455 million	$405 to $425 million
Adjusted EBITDA1	>$150 million Excludes potential CNP-104 option exercise	>$120 million Excludes potential CNP-104 option exercise

Get the next $IRWD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IRWD

Date	Price Target	Rating	Analyst
9/9/2024	$5.00	Market Perform	Leerink Partners
8/8/2024	$12.00 → $4.00	Overweight → Equal Weight	CapitalOne
1/17/2024	$21.00	Buy	Craig Hallum
12/14/2023	$20.00	Overweight	Wells Fargo
11/9/2023	$21.00	Buy	Jefferies
9/28/2023	$22.00	Mkt Outperform	JMP Securities
9/2/2022	$15.00	Overweight	CapitalOne
4/22/2022	$16.00	Overweight	Piper Sandler

More analyst ratings

$IRWD
Financials

Live finance-specific insights

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
11/7/24 7:00:00 AM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li
10/24/24 4:00:00 PM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its second quarter 2024 results and recent business performance. "We continued to make progress across our portfolio in the second quarter," said Tom McCourt, chief executive off
8/8/24 7:00:00 AM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care

$IRWD
Leadership Updates

Live Leadership Updates

Memo Therapeutics AG appoints Paul Carter as Chairperson
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
7/8/24 7:00:00 AM ET
$IMTX
$IRWD
$VECT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he
12/1/21 7:30:00 AM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwood's Leadership Team and oversee the company's Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "John's deep legal experience and proven track record, in particular his experience at highly focused healthcare companies, arm him with invaluable expertise that will strongly benefit Ironwood by helping accelerate our business priorities and reinforce our efforts to make a difference for people l
8/3/21 7:30:00 AM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website for 1 year following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company
11/13/24 4:01:00 PM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
11/7/24 7:00:00 AM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
– New safety and tolerability data show high treatment compliance with apraglutide, low incidence of injection site reactions and adverse events associated with GI tolerability – – Findings reinforce the clinical profile of once-weekly apraglutide; Ironwood expects to complete U.S. regulatory submission in Q1 2025 – – One apraglutide poster recognized as presidential poster recipient – – New linaclotide data shed light on treatment outcomes across patient demographics – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgr
10/28/24 7:00:00 AM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care

Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday. Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday's session after the company announced a $150 million share repurchase program and reaffirmed its forward guidance. Asana said its board of directors approved a stock repurchase program authorizing the company to repurchase up to $150 million of its Class A common stock through June 30, 2025. Asana shares jumped 13.4% to $12.90 on Friday. Here are some other big stocks recording gains in today’s session. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares jumped 39.2% to $171.89 after the company announced FDA approval of an expansion to
6/21/24 10:45:13 AM ET
$ADTN
$ASAN
$BA
$CABA
Telecommunications Equipment
Utilities
Computer Software: Prepackaged Software
Technology
Ironwood Pharmaceuticals Appoints Sravan K. Emany As Senior Vice President, Chief Operating Officer, And Chief Financial Officer; Emany Previously Served As Senior Vice President, CFO Since December 2021
- Form8
6/20/24 4:13:46 PM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
Ironwood Pharmaceuticals Will Present Late-breaking Data During The 2024 Digestive Disease Week Meeting From Its Phase 3 STARS Trial Of Apraglutide For Short Bowel Syndrome With Intestinal Failure
New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24 Additional secondary endpoints show significant increases in days off PS and clinical responder rates with apraglutide, including achieving enteral autonomy in both stoma and CIC patients – Data from largest GLP-2 Phase III study to date adds to body of evidence on safety and efficacy of once-weekly apraglutide in adults with SBS-IF – New details on safety and tolerability to be presented; showing apraglutide to be well tolerated with a safety profile consistent with previousl
5/21/24 6:13:47 AM ET
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care

Ironwood Pharmaceuticals Lowers 2024 Guidance: Now Expects Sales Between $405M-$425M (Prior $435M-$455M) Vs. 447.9M Consensus; Sees Adjusted EBITDA Above $120M

Chat with this insight

Recent Analyst Ratings for $IRWD

$IRWD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)

Emany Sravan Kumar bought $100,216 worth of shares (10,684 units at $9.38), increasing direct ownership by 4% to 301,733 units (SEC Form 4)

SEC Form 4: Emany Sravan Kumar bought $300,119 worth of shares (36,072 units at $8.32), increasing direct ownership by 24% to 188,730 units

$IRWD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, Chief Business Officer Davis Andrew sold $21,869 worth of shares (5,360 units at $4.08), decreasing direct ownership by 2% to 284,685 units (SEC Form 4)

SVP, COO and CFO Emany Sravan Kumar sold $44,884 worth of shares (11,001 units at $4.08), decreasing direct ownership by 3% to 309,572 units (SEC Form 4)

Director Denner Alexander J was granted 3,282 shares, increasing direct ownership by 2% to 152,104 units (SEC Form 4)

$IRWD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Ironwood Pharma with a new price target

Ironwood Pharma downgraded by CapitalOne with a new price target

Craig Hallum initiated coverage on Ironwood Pharma with a new price target

$IRWD Financials

Live finance-specific insights

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

$IRWD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Ironwood Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

$IRWD Leadership Updates

Live Leadership Updates

Memo Therapeutics AG appoints Paul Carter as Chairperson

Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

$IRWD SEC Filings

$IRWD Press Releases

Fastest customizable press release news feed in the world

$IRWD Market Insights

Live Market Insights

SEC Form SCHEDULE 13G filed by Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday

Ironwood Pharmaceuticals Appoints Sravan K. Emany As Senior Vice President, Chief Operating Officer, And Chief Financial Officer; Emany Previously Served As Senior Vice President, CFO Since December 2021

Ironwood Pharmaceuticals Will Present Late-breaking Data During The 2024 Digestive Disease Week Meeting From Its Phase 3 STARS Trial Of Apraglutide For Short Bowel Syndrome With Intestinal Failure

Recent Analyst Ratings for
$IRWD

$IRWD
Insider Purchases

$IRWD
Insider Trading

$IRWD
Analyst Ratings

$IRWD
Financials

$IRWD
Large Ownership Changes

$IRWD
Leadership Updates

$IRWD
SEC Filings

$IRWD
Press Releases

$IRWD
Market Insights